The Nasdaq Biotechnology Index rose 3.2% after Moderna and Merck's mRNA melanoma vaccine succeeded in a large-scale Phase 3 trial.
Jin1008/19, 08:35 PM
Related assets
Coming up for MRNA
Explore next
Latest MRNA news
Jin1010/23, 05:33 AM
Jin1010/23, 03:02 AM
Jin1010/23, 12:41 AM